Last reviewed · How we verify
NCT03270007
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
Phase 4 trial testing Vinorelbine in Primary Breast Cancer in 304 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Tao OUYANG |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 304 |
| Start date | 10 November 2017 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Vinorelbine (vinorelbine) — full drug profile →
Conditions studied
- Primary Breast Cancer — all drugs for Primary Breast Cancer →
Sponsor
Tao OUYANG — full company profile →
Who can join
Adults 18 to 66, female only, with Primary Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase IV, single-center, prospective, open-label, randomized,controlled study
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy.
Wang X, He Y, Li J, Wang T, et al · · 2024 · PMID 39604957 · DOI 10.1186/s12905-024-03441-0
Verify or expand the search:
- PubMed search for NCT03270007
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vinorelbine
Trials testing the same drug.
- NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
- NCT07021989 — ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Phase 2 · not yet recruiting
- NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
- NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
- NCT06908304 — A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC · Phase 3 · recruiting
Other Tao OUYANG trials
Trials by the same sponsor.
- NCT03711877 — Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) · Phase 3 · unknown
- NCT01019616 — Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03270007 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tao OUYANG
- Last refreshed: 28 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03270007.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing